Electroporation (EP) stands out as a promising non-viral plasmid delivery strategy, although achieving optimal transfection efficiency in vivo remains a challenge. A noteworthy advancement in the field of in vivo EP is the application of hyaluronidase, an enzyme with the capacity to degrade hyaluronic acid in the extracellular matrix, which thereby enhances DNA transfer efficiency by 2- to 3-fold. This paper focuses on elucidating the mechanism of hyaluronidase’s impact on transfection efficiency. We demonstrate that hyaluronidase promotes a more uniform distribution of plasmid DNA (pDNA) within skeletal muscle. Additionally, our study investigates the effect of the timing of hyaluronidase pretreatment on EP efficiency by including time intervals of 0, 5, and 30 min between hyaluronidase treatment and the application of pulses. Serum levels of the pDNA-encoded transgene reveal a minimal influence of the hyaluronidase pretreatment time on the final serum protein levels following delivery in both mice and rabbit models. Leveraging bioimpedance measurements, we capture morphological changes in muscle induced by hyaluronidase treatment, which result in a varied pDNA distribution. Subsequently, these findings are employed to optimize EP electrical parameters following hyaluronidase treatment in animal models. This paper offers novel insights into the potential of hyaluronidase in enhancing the effectiveness of in vivo EP, as well as guides optimized electroporation strategies following hyaluronidase use.
Obesity-related asthma (OA) is a severe asthma endotype that disproportionately affects children from minority ethnic groups. We previously identified downregulation of RPS27L (40S ribosomal protein S27-like) in CD4+ (T-helper) cells from children with OA compared to cells from healthy-weight asthma (HwA) that was associated with the C allele at rs6494395 locus. In keeping with elevated allele frequencies in populations with Latino and African ancestries, we found higher allele frequency of rs6494395 in Hispanic and African American children with OA. Therefore, we tested the hypothesis that rs6494395 is ancestry-specific. We performed global and local genomic ancestry analysis using the programs ADMIXTURE and RFMix, respectively, to characterize the genetic ancestry of the cohort and to identify the ancestry of the genomic region containing the variant rs6494395 in the same multi-ethnic pediatric cohort where the effect of the variant on obese-related asthma was discovered. Our results indicate that rs6494395 is of African genetic ancestry. Understanding the genetic underpinnings of pediatric OA in diverse populations can improve precision medicine approaches and address health disparities in asthma outcomes.